Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population

Journal of Lipid Research

Volumn 56, Issue 4, 2015, Pages 920-926

  Ding, Lin ^a   Song, An ^a,b   Dai, Meng ^a   Xu, Min ^a   Sun, Wanwan ^a   Xu, Baihui ^a   Sun, Jichao ^a   Wang, Tiange ^a   Xu, Yu ^a   Lu, Jieli ^a   Wang, Weiqing ^a   Bi, Yufang ^a   Ning, Guang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cardiovascular risk; Epidemiology; Lipid; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; LIPOPROTEIN A;

ADULT; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; PREDIABETIC STATE;

AGED; CHINA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDIABETIC STATE; PREVALENCE;

EID: 84927558530     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P049015     Document Type: Article

References (33)

1. Berg, K. 1963. A new serum type system in man - the Lp system. Acta Pathol. Microbiol. Scand. 59: 369-382.
2. Kronenberg, F., and G. Utermann. 2013. Lipoprotein (a): resurrected by genetics. J. Intern. Med. 273: 6-30.
3. Erqou, S., S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh. 2009. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. J. Am. Med. Assoc. 302: 412-423.
4. Kamstrup, P. R., A. Tybjærg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. J. Am. Med. Assoc. 301: 2331-2339.
5. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, and S. Rust. 2009. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
6. Jenkins, A. J., Steele, E. Janus, J. Santamaria, and J. Best. 1992. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 35: 1055-1059.
7. Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J. L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. J. Am. Med. Assoc. 263: 35-36.
8. Chang, C. J., J. T. Kao, T. J. Wu, F. H. Lu, and T. Y. Tai. 1995. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care. 18: 1191-1194.
9. Rainwater, D. L., J. W. MacCluer, M. P. Stern, J. L. VandeBerg, and S. M. Haffner. 1994. Effects of NIDDM on lipoprotein (a) concentration and apolipoprotein (a) size. Diabetes. 43: 942-946.
10. Mora, S., P. R. Kamstrup, N. Rifai, B. G. Nordestgaard, J. E. Buring, and P. M. Ridker. 2010. Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56: 1252-1260.
11. Ye, Z., P. C. Haycock, D. Gurdasani, C. Pomilla, S. M. Boekholdt, S. Tsimikas, K. T. Khaw, N. J. Wareham, M. S. Sandhu, and N. G. Forouhi. 2014. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes. 63: 332-342.
12. Kamstrup, P. R., and B. G. Nordestgaard. 2013. Lipoprotein (a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 1: 220-227.
13. Li, M., Y. Xu, M. Xu, L. Ma, T. Wang, Y. Liu, M. Dai, Y. Chen, J. Lu, and J. Liu. 2012. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J. Clin. Endocrinol. Metab. 97: 2033-2038.
14. Huang, Y., Y. Bi, M. Xu, Z. Ma, Y. Xu, T. Wang, M. Li, Y. Liu, J. Lu, and Y. Chen. 2012. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler. Thromb. Vasc. Biol. 32: 2321-2326.
15. Tomioka, K., J. Iwamoto, K. Saeki, and N. Okamoto. 2011. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study. J Epidemiol. 21: 459-465.
16. Marcovina, S. M., J. J. Albers, A. M. Scanu, H. Kennedy, F. Giaculli, K. Berg, R. Couderc, F. Dati, N. Rifai, I. Sakurabayashi, et al. 2000. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin. Chem. 46: 1956-1967.
17. WHO Consultation. 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. World Health Organization, Geneva, Switzerland.
18. Levy, J. C., D. R. Matthews, and M. P. Hermans. 1998. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 21: 2191-2192.
19. Bell, D. S., and F. Ovalle. 1998. Metformin lowers lipoprotein(a) levels. Diabetes Care. 21: 2028.
20. Tack, C. J., P. Smits, P. N. DeMacker, and A. F. Stalenhoef. 1999. Effect of troglitazone on lipoprotein(a) levels in obese subjects. Diabetes Care. 22: 1752-1753.
21. Heller, F. R., J. Jamart, P. Honore, G. Derue, V. Novik, L. Galanti, A. Parfonry, J. C. Hondekijn, and M. Buysschaert. 1993. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care. 16: 819-823.
22. Kiayias, J. A., E. D. Vlachou, and E. L. Papadodima. 1999. Metformin and lipoprotein(a) levels. Diabetes Care. 22: 859.
23. Song, K. H., Y. B. Ahn, K. H. Yoon, B. Y. Cha, K. W. Lee, H. Y. Son, and S. K. Kang. 1999. The effect of long-term glycaemic control on serum lipoprotein(a) levels in patients with type 2 diabetes mellitus. Diabet. Med. 16: 1036-1039.
24. Ritter, M. M., W. O. Richter, K. Lyko, and P. Schwandt. 1992. Lp(a) serum concentrations and metabolic control. Diabetes Care. 15: 1441-1442.
25. Haffner, S. M., P. A. Morales, M. P. Stern, and M. K. Gruber. 1992. Lp (a) concentrations in NIDDM. Diabetes. 41: 1267-1272.
26. Angelin, B. 2013. Fifty years of lipoprotein (a)-the Magical Mystery Tour continues. J. Intern. Med. 273: 3-5.
27. von Eckardstein, A., S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre. 1997. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein AI and lipoprotein (a). J. Clin. Endocrinol. Metab. 82: 3367-3372.
28. Olivecrona, H., A. G. Johansson, E. Lindh, S. Ljunghall, L. Berglund, and B. Angelin. 1995. Hormonal regulation of serum lipoprotein (a) levels contrasting effects of growth hormone and insulin-like growth factor-I. Arterioscler. Thromb. Vasc. Biol. 15: 847-849.
29. Edén, S., O. Wiklund, J. Oscarsson, T. Rosén, and B-A. Bengtsson. 1993. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp (a) and HDL cholesterol concentrations. Arterioscler. Thromb. Vasc. Biol. 13: 296-301.
30. Chennamsetty, I., T. Claudel, K. M. Kostner, A. Baghdasaryan, D. Kratky, S. Levak-Frank, S. Frank, F. J. Gonzalez, M. Trauner, and G. M. Kostner. 2011. Farnesoid X receptor represses hepatic human APOA gene expression. J. Clin. Invest. 121: 3724-3734.
31. Fang, Q., H. Li, Q. Song, W. Yang, X. Hou, X. Ma, J. Lu, A. Xu, and W. Jia. 2013. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care. 36: 2810-2814.
32. Neele, D. M., E. C. De Wit, and H. M. Princen. 1999. Insulin suppresses apolipoprotein (a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia. 42: 41-44.
33. Lanktree, M. B., S. S. Anand, S. Yusuf, and R. A. Hegele. 2010. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 3: 39-46.